PACIRA BIOSCIENCES, INC. Accounts Receivable, Allowance for Credit Loss
PACIRA BIOSCIENCES, INC. (PCRX) had Accounts Receivable, Allowance for Credit Loss of $0 as of 2020-09-30, per its 10-Q filed 2020-10-30.
Discontinued › Balance Sheet › Assets
us-gaap:AllowanceForDoubtfulAccountsReceivable · last filed 2020-10-30
- 2020-09-30: Accounts Receivable, Allowance for Credit Loss $0.00.
- 2020-06-30: Accounts Receivable, Allowance for Credit Loss $0.00.
- 2020-03-31: Accounts Receivable, Allowance for Credit Loss $0.00.
| Period end | Accounts Receivable, Allowance for Credit Loss |
|---|---|
| 2020-09-30 | $0.00 10-Q · filed 2020-10-30 |
| 2020-06-30 | $0.00 10-Q · filed 2020-08-06 |
| 2020-03-31 | $0.00 10-Q · filed 2020-05-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| Savara Inc (SVRA) | United States | $1.044B | -9.10 |
| Corvus Pharmaceuticals, Inc. (CRVS) | United States | $0.994B | -23.25 |
| MANNKIND CORP (MNKD) | United States | $1.058B | -30.41 |
| Alto Neuroscience, Inc. (ANRO) | United States | $1.065B | -11.02 |
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 | |
| Jade Biosciences, Inc. (JBIO) | United States | $0.936B | -9.21 |
| Amphastar Pharmaceuticals, Inc. (AMPH) | United States | $1.116B | 10.93 |